13
May
2025
Biologic Drug Discovery Made Faster: Peyton Greenside on The Long Run
Peyton Greenside is today’s guest on The Long Run. Peyton is the co-founder and CEO of San Mateo, Calif.-based BigHat Biosciences. The company was started in 2019 to build on advances in synthetic biology and machine learning to design antibody drugs with a variety of different properties, faster. The company has gone on to raise more than $100 million in... Read More
8
May
2025
NewLimit’s Anti-Aging Bounty, a Twist Spinout, & AI Coming to the FDA
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
May
2025
A Sublime Experience: Views of Timmerman Traverse for Damon Runyon Cancer Research
Kathmandu, Nepal We did it together. The Timmerman Traverse for Damon Runyon Cancer Research Foundation completed a splendid expedition to Everest Base Camp on Apr. 23, 2025. This trip succeeded on every count. All 17 members of the team made it to the mountaineering camp at 17,600 feet / 5,364 meters. We exceeded our $700,000 fundraising goal for high-risk /... Read More
14
Apr
2025
Finding New Targets for Cancer Drugs: Kevin Parker on The Long Run
Kevin Parker is today’s guest on The Long Run. Kevin is the co-founder and CEO of South San Francisco-based Cartography Biosciences. The company is using multi-omic tools to map out which targets are specifically expressed on cancer cells. The idea is to find new, precise targets that antibody drugs can aim for. Cartography got started during the pandemic, raised a... Read More
10
Apr
2025
FDA in Crisis, Parker Institute Snags Big Fish, & Merida Megaround
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Apr
2025
Meet the Timmerman Traverse for Life Science Cares 2025 Team
The 5th annual Timmerman Traverse for Life Science Cares is fired up and ready for outdoor adventure in 2025. We’re on a mission to raise $1 million to fight poverty. This year’s team is preparing for a pair of challenging hikes in the Pacific Northwest, Aug. 18-19. We’ll cover 20 miles of trails, ascend 7,000 vertical feet, and savor some... Read More
3
Apr
2025
FDA Gutted, Novartis Kidney Drug Pays Off, and Isomorphic Raises a Fortune
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Apr
2025
Timmerman Traverse for Damon Runyon Hits $700K Goal, Fueling Cancer Research
Times are tough in biotech, but this is an industry where we learn, adapt, and move forward. I’m proud to announce that the 2025 Timmerman Traverse for Damon Runyon Cancer Research Foundation has hit its fundraising goal of $700,000 to support high-risk / high-reward cancer research. We stand at $702,555 in closed donations. Our team of 16 hikers is now... Read More
31
Mar
2025
Relationships That Make TechBio Go ‘Round: David Roblin on The Long Run
David Roblin is today’s guest on The Long Run podcast. David is the CEO of London-based Relation Therapeutics. The company uses multi-omic tools to look for drug targets in human tissue samples. It seeks to find the relationships between perturbed biological states and disease, with the help of machine learning. Relation emphasizes relationships in another sense as well – the... Read More
27
Mar
2025
A Moment of Peril and Promise
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Mar
2025
Curevo and Arbor Defy Gravity, Cargo Hits the Wall, & AZ Bets on In Vivo
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Mar
2025
See the Photos from TR10 West
Thanks to everyone who attended the TR10 anniversary party Mar. 13 at Adaptive Biotechnologies. The toasts and roasts were funny, perceptive and heartfelt. It was a joyous occasion. Enjoy a few photos. Click to enlarge. Photos by Robert Wade.
18
Mar
2025
See the Photos from TR10 East
Thanks to everyone who attended the TR10 anniversary party Mar. 6 at Alnylam Pharmaceuticals. The toasts and roasts were funny, perceptive and heartfelt. There was a joyful community spirit in the room. Enjoy a few photos. Click to enlarge. Photos by Mike Mejia.
18
Mar
2025
Arbor Survives Winter, Gets $73.9M to Take Gene Editing to the Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Mar
2025
CAR-T cell Therapies Made In the Body: Andy Scharenberg on The Long Run
Andy Scharenberg is today’s guest on The Long Run. Andy is the co-founder and CEO of Seattle-based Umoja Biopharma. The company is developing in vivo CAR-T cell therapies. The idea is to use gene therapy, delivered in a single shot, that can reprogram T cells of the immune system to recognize markers on cancer cells and then hunt down cancer... Read More
17
Mar
2025
Curevo Captures $110M to Develop a More Tolerable Shingles Vaccine
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Mar
2025
Protagonist Delivers, BMS Bargain Hunts, and Zealand Goes Major League
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Mar
2025
Biotech Legend Retires, Jazz Buys Glioma Drug, & FDA Shakeup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Mar
2025
Flashback: Q&A on Founding TR
[Dear Readers: This Q&A from the Knight Science Journalism at MIT blog on Feb. 3, 2015 captures my thoughts on founding TR and where biotech was going. Thank you for your support. — Luke ] By Wade Roush For writers, part of the fuss about the Web explosion of the late 1990s was that it was finally possible to cut... Read More
3
Mar
2025
A Woman in the TechBio Arena: Najat Khan on The Long Run
Najat Khan is today’s guest on The Long Run. She is the chief R&D and chief commercial officer of Salt Lake City-based Recursion. The company is one of the first-generation companies that have sought to reinvent drug R&D from the ground up with automated technologies that collect a lot of biological data and then analyze that data with AI algorithms.... Read More